ArticleCancer management and research2025
Prognostic Significance of High-Risk versus Very High-Risk Classification in Non-Surgically Managed Prostate Cancer: A Retrospective Cohort Study.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinicopathological Profile of Prostate Cancer Patients at a Tertiary Hospital in the Eastern Cape, South Africa.International journal of environmental research and public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Risk stratification is one of the most critical parameters guiding treatment decisions in nonmetastatic prostate cancer. Although it is well established that high risk (HR) and very high risk (VHR) groups diverge prognostically, the real-world impact of this distinction in non-surgically managed patient populations has been less extensively evaluated. Methods: In this retrospective study, 81 patients with nonmetastatic prostate cancer were analyzed (HR: n=24; VHR: n=57). All patients received androgen deprivation therapy (ADT), and 65.4% additionally underwent radiotherapy (RT). Clinical and pathological characteristics, early PSA responses, overall survival (OS), and disease-free survival (DFS) were compared between HR and VHR groups. Results: At diagnosis, VHR patients presented with higher PSA values, worse Gleason scores, and more advanced stages. Although PSA responses at three and six months were similar between groups, long-term outcomes were significantly inferior in the VHR cohort. Median OS for the entire cohort was 72.1 months in VHR patients versus 97.1 months in HR patients (p=0.039). Among those receiving RT, the difference was preserved (HR: 104.5 months vs VHR: 75.1 months; p=0.032). Median DFS was 23.3 months in the VHR group and 44.5 months in the HR group (p=0.026). During follow-up, recurrence/metastasis occurred in 54.4% of VHR patients compared with 16.7% of HR patients (p=0.002). Conclusion: Our findings show that the VHR classification maintains strong prognostic value even in non-surgically managed patients, underscoring its role as a biologically distinct and aggressive disease entity. Standard RT+ADT seems insufficient in this subgroup. The study supports exploring intensified treatment strategies, such as prolonged ADT, brachytherapy boost, pelvic nodal RT, and, where appropriate, novel androgen receptor signaling inhibitors or chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.